- Home
- SHLS vs MLTX Comparison
SHLS vs MLTX Comparison
Compare SHLS & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHLS | MLTX |
|---|---|---|
| Founded | 1996 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SHLS | MLTX |
|---|---|---|
| Price | $5.86 | $17.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | $9.29 | ★ $25.70 |
| AVG Volume (30 Days) | ★ 5.3M | 1.2M |
| Earning Date | 05-27-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $475,331,000.00 | N/A |
| Revenue This Year | $20.21 | N/A |
| Revenue Next Year | $11.11 | N/A |
| P/E Ratio | $29.48 | ★ N/A |
| Revenue Growth | ★ 19.07 | N/A |
| 52 Week Low | $2.71 | $5.95 |
| 52 Week High | $11.36 | $62.75 |
Technical Indicators
Market Signals| Indicator | SHLS | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.69 | 57.93 |
| Support Level | $4.21 | $14.84 |
| Resistance Level | $6.26 | $19.15 |
| Average True Range (ATR) | 0.78 | 0.99 |
| MACD | -0.52 | -0.02 |
| Stochastic Oscillator | 6.87 | 57.35 |
Price Performance
Historical ComparisonAbout SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.